HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A double blind cross-over comparison of bunitrolol and placebo in the treatment of angina pectoris.

Abstract
In 20 patients with stable angina pectoris, o-[3-(tert.-butylamino)-2-hydroxypropoxy]-benzonitrile (bunitrolol) was compared with placebo in a double blind cross-over trial, with monthly treatment periods. There was no difference in the subjective condition of the patient. The bunitrolol treated patients showed a significantly better work capacity (P less than 0.05) and pressure-rate product (P less than 0.01) in the exercise tests. No significant difference could be found in the ST-segment changes. The bunitrolol patients showed a significant reduction in heart rate at rest (P less than 0.01); a significant difference in blood pressure was not found. Bunitrolol is an effective beta-adrenergic blocker, without side-effects in this trial.
AuthorsJ J Jonker, J de Klerk, G J den Ottolander
JournalArzneimittel-Forschung (Arzneimittelforschung) Vol. 31 Issue 7 Pg. 1140-2 ( 1981) ISSN: 0004-4172 [Print] Germany
PMID6115654 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Placebos
  • Propanolamines
Topics
  • Adult
  • Aged
  • Angina Pectoris (drug therapy)
  • Blood Pressure (drug effects)
  • Double-Blind Method
  • Drug Evaluation
  • Electrocardiography
  • Exercise Test
  • Heart Rate (drug effects)
  • Humans
  • Middle Aged
  • Placebos
  • Propanolamines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: